Eye drops for inhibiting pathological angiogenesis of eyes and preparation method thereof
By combining ashwagen A, solvent-promoting agent, thickening agent and pH regulator in eye drops, the problem of insoluble in water and organic solvents is solved, and effective eye drops are prepared, which significantly improves the number of cells. Pathological angiogenesis in the eyes has achieved effective retention and therapeutic effects of ashwacin A.
Patent Information
- Application Number
- CN202411093468.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-09
- Publication Date
- 2024-11-22
AI Technical Summary
The prior art is difficult to make ashwacin A into eye drops, mainly because it is insoluble in water and the commonly used organic solvents are cytotoxic, resulting in short eye irritation symptoms and retention time, and lack of effective eye anti-VEGF eye drops. .
Using 0.01-0.8mg/L of ashwagen A, combined with solvent-promoting agents, thickening agents, antibacterial agents and pH regulators, eye drops are prepared through appropriate amounts of injection water and filtration to ensure the dissolution of ashwagen A. Sex and retention time, avoid systemic side effects and form suitable eye drops.
Galaxacin A eye drops significantly improve pathological angiogenesis in the eye, have good biocompatibility and therapeutic effects, and have clear therapeutic effects on pathological angiogenesis in the eye, and have no systemic side effects.
Smart Images

Figure HDA0004987213690000011 
Figure HDA0004987213690000012 
Figure HDA0004987213690000021
Abstract
Description
Technical Field
[0001] The invention relates to eye drops, in particular to eye drops for inhibiting ocular pathological angiogenesis and a preparation method thereof. Background Art
[0002] Pathological angiogenesis of the eye refers to abnormal growth of new blood vessels in the eye. Pathological angiogenesis of the ocular surface, also known as corneal neovascularization, is a pathological change rather than an independent corneal disease. Under normal circumstances, the cornea is colorless, transparent and has no blood vessels. When the cornea is covered with new blood vessels, these blood vessels will block part of the light, causing blurred or reduced vision. Pathological angiogenesis of the ocular surface can lead to visual impairment and is the second leading cause of blindness worldwide.
[0003] Trauma, infection, wearing low-oxygen-permeability corneal contact lenses, corneal degeneration and malnutrition can cause ocular surface ischemia and inflammatory response, which leads to increased production of vascular endothelial growth factor (VEGF) and induces pathological angiogenesis. Previous studies have found that the small molecule compound withaferin A extracted from South African somniferum may prevent NF-κB activation by inhibiting the activation of IKKβ; it is believed to have anti-inflammatory and anti-tumor effects; the team's previous research has confirmed that withaferin A has dual effects of anti-hypoxic damage and anti-VEGF, and may become a potential raw material for ocular drugs. Patent number: 201910398536.6, discloses a "use of Withaferin A in the preparation of drugs for the treatment of fundus ischemic diseases", but the invention uses a subperitoneal implant pump to systemically administer withaferin A solution to treat fundus lesions. There are also related basic studies internationally that withaferin A may have an inhibitory effect on corneal blood vessels, but all of them use the method of systemic administration of withaferin A solution (such as subperitoneal injection). Mohan R, Bargagna-Mohan P et al. Academic Press, 2016, Investigative Ophthalmology & Visual Science, 2012, PLoS One, 2015, Investigative Ophthalmology & Visual Science, 2005 Chemistry & Biology, 2007, 14 (6): 623-634. All the above documents are basic research, and only withaferin A is simply dissolved and then administered systemically, and no attempt has ever been made to make it into related pharmaceutical preparations. A large number of studies by our research group have confirmed that withaferin A is an anti-VEGF, angiogenic compound. If it is used systemically, it will inhibit the formation of cardiovascular and cerebrovascular collateral circulation and easily induce cardiovascular and cerebrovascular accidents. Therefore, it is obviously more harmful than beneficial to make it into a pharmaceutical preparation for systemic use. Therefore, our team turned to study making it into an ophthalmic preparation for local use to avoid its cardiovascular and cerebrovascular side effects. In fact, withaferin A has a small molecular weight, a stable structure, and is lipophilic. It is undoubtedly directly effective, has good permeability, is easy to use, and has the advantages of small systemic side effects when made into eye drops. However, there are no research reports on withaferin A eye drops. This is because there are technical barriers to making withaferin A into eye drops: 1. Withaferin A is insoluble in water, and the previously recognized organic solvents of withaferin A (such as methanol, DMSO) have certain cytotoxicity, which can cause damage and eye irritation symptoms when used directly on the ocular surface. 2. The preparation of withaferin A into ophthalmic preparations requires the addition of excipients and other auxiliary materials to prolong the retention time on the ocular surface in order to achieve better therapeutic effects and less frequency of medication. Therefore, solving these problems is the key to making withaferin A, a small molecule compound that has not yet been used medicinally, into eye drops.
[0004] The eye drops of the present invention solve the technical barriers of preparing withaferin A into eye drops, and have a good therapeutic effect on pathological angiogenesis of the eye, especially on the ocular surface. At present, there are no eye drops that inhibit ocular angiogenesis by anti-VEGF, so it has clear innovation and market value. Summary of the invention
[0005] To achieve the above-mentioned purpose, the technical solution adopted by the present invention is: an eye drop for inhibiting pathological angiogenesis in the eye, wherein the eye drop contains the following ingredients by weight-to-volume ratio: 0.01-0.8 mg / L of withaferin A, 1-25 g / L of a dissolution promoter, 2-40 g / L of a thickener, 0.04-0.2 g / L of an antibacterial agent, an appropriate amount of an isotonicity regulator and a pH regulator, and the remainder is water for injection.
[0006] A further preferred embodiment is that the dissolution agent is one of Tween 80, propylene glycol, poloxamer, polyethylene glycol, and β-cyclodextrin, or a mixture of any of them.
[0007] A further preferred embodiment is that the thickener is one or a mixture of any of methyl cellulose, polyvinyl alcohol, polyethylene glycol, sodium hyaluronate, povidone, hydroxypropyl methyl cellulose, hydroxypropyl ethyl cellulose, and carboxymethyl cellulose.
[0008] A further preferred embodiment is that the pH adjuster is one of boric acid, borate buffer, phosphate buffer, citrate buffer or a mixture of any of them, and the amount of the pH adjuster is based on adjusting the pH value of the eye drops to 6.0-8.0.
[0009] A further preferred embodiment is that the osmotic pressure regulator is one of sodium chloride, potassium chloride, boric acid, glucose, and glycerol, or a mixture of any of them; and the amount of the osmotic pressure regulator is used to adjust the osmotic pressure molar concentration ratio to 0.9 to 1.1.
[0010] A further preferred embodiment is that the antibacterial agent is one or a mixture of any of ethylparaben, benzalkonium chloride, benzalkonium bromide and polyquaternium-1.
[0011] The method of eye drops for inhibiting ocular pathological angiogenesis comprises the following steps:
[0012] The first step is to weigh withaferin A and a solubilizing agent in a corresponding weight-to-volume ratio, mix them and stir them evenly for later use;
[0013] Step 2: Weigh the corresponding weight-volume ratio of thickener, pH adjuster, isotonic adjuster, and antibacterial agent, heat and stir in a 60°C water bath until clear and translucent, and cool to room temperature;
[0014] The third step is to add the mixed solution of the first step to the solution of the second step and make up to volume with water for injection;
[0015] The fourth step is to filter and sterilize the prepared eye drops through a 0.22 μm microporous filter membrane and aseptically package them.
[0016] The preparation method of the present invention includes but is not limited to various medically acceptable eye preparations such as eye drops, eye wash solutions, solid mixtures (dissolved before use), concentrated solutions (diluted before use), eye ointments, eye gels, etc.
[0017] The eye drops for inhibiting ocular pathological angiogenesis are used in the preparation of the treatment of ocular pathological angiogenesis.
[0018] The eye drops of the present invention have the following advantages:
[0019] (1) The eye drops of the present invention make withaferin A have good solubility and prolong its retention time on the ocular surface. Compared with withaferin A dissolved in traditional solvents, the withaferin A dosage form disclosed in the present invention can better exert the pharmacological effects of withaferin A and has a clear therapeutic effect on pathological angiogenesis of the eye. The withaferin A eye drops have good biocompatibility, moderate viscosity, and are non-irritating to the eyes. Therefore, they have transformation value.
[0020] (2) The eye drops of the present invention not only have the anti-inflammatory, anti-oxidative stress and anti-VEGF effects of withaferin A itself, but also have the advantages of direct onset, good permeability, convenient use and small systemic side effects of local ophthalmic preparations.
[0021] (3) The active ingredient withaferin A in the eye drops disclosed in the present invention has good solubility and permeability. Therefore, when the concentration of withaferin A in the preparation is high, it can treat neovascularization deeper in the eye, such as: iris neovascularization, anterior chamber angle neovascularization and fundus neovascularization. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 Withaferin A eye drops improved the pathological angiogenesis of the cornea of mice induced by alkali burns, while the use of Withaferin A solution alone had no significant effect;
[0023] Figure 2 Immunofluorescence further confirmed that withaferin A eye drops significantly improved the pathological angiogenesis of the cornea of mice caused by alkali burns;
[0024] Figure 3 Withaferin A eye drops improve corneal opacity caused by alkali burn in mice;
[0025] Figure 4Withaferin A eye drops improved the pathological angiogenesis of the mouse cornea induced by suture method, while withaferin A solution had no significant effect;
[0026] Figure 5 Immunofluorescence further confirmed that withaferin A eye drops significantly improved the pathological angiogenesis of the mouse cornea induced by suture method. DETAILED DESCRIPTION
[0027] The following examples and experimental examples are merely provided to further illustrate the present invention and should not be construed as limiting the present invention.
[0028] Example 1
[0029] The present embodiment provides an eye drop for inhibiting pathological angiogenesis in the eye. The withaferin A eye drop contains the following ingredients by weight to volume ratio: 0.01 mg / L withaferin A, 1 g / L Tween 80, 5.6 g / L povidone K30, 0.1 g / L benzalkonium chloride, 6.2 g / L sodium chloride, 4 g / L sodium dihydrogen phosphate, 7.1 g / L disodium hydrogen phosphate, and the balance is water for injection.
[0030] The dosage of the sodium dihydrogen phosphate and disodium hydrogen phosphate is based on adjusting the pH value of the eye drops to 6.8.
[0031] The amount of sodium chloride used is to adjust the osmotic pressure molar concentration ratio to 0.9.
[0032] The method of eye drops for inhibiting ocular pathological angiogenesis comprises the following steps:
[0033] The first step is to weigh withaferin A and Tween 80 in a corresponding weight-to-volume ratio, mix them and stir them evenly for later use;
[0034] Step 2: weigh corresponding weight-volume ratios of povidone K30, benzalkonium chloride, sodium chloride, sodium dihydrogen phosphate, and sodium hydrogen phosphate, heat and stir in a 60° C. water bath until clear and translucent, and cool to room temperature;
[0035] The third step is to add the mixed solution of the first step to the solution of the second step and make up to volume with water for injection;
[0036] The fourth step is to filter and sterilize the prepared eye drops through a 0.22 μm microporous filter membrane and aseptically package them.
[0037] The eye drops for inhibiting ocular pathological angiogenesis are used in the preparation of the treatment of ocular pathological angiogenesis.
[0038] Example 2
[0039] The present embodiment provides an eye drop for inhibiting pathological angiogenesis in the eye. The withaferin A eye drop contains the following ingredients by weight to volume ratio: 0.1 mg / L withaferin A, 5 g / L Tween 80, 5.6 g / L povidone K30, 0.1 g / L benzalkonium chloride, 6.2 g / L sodium chloride, 4 g / L sodium dihydrogen phosphate, 7.1 g / L disodium hydrogen phosphate, and the balance is water for injection.
[0040] The dosage of the sodium dihydrogen phosphate and disodium hydrogen phosphate is based on adjusting the pH value of the eye drops to 6.8.
[0041] The amount of sodium chloride used is to adjust the osmotic pressure molar concentration ratio to 0.9.
[0042] The method of eye drops for inhibiting ocular pathological angiogenesis comprises the following steps:
[0043] The first step is to weigh withaferin A and Tween 80 in a corresponding weight-to-volume ratio, mix them and stir them evenly for later use;
[0044] Step 2: weigh corresponding weight-volume ratios of povidone K30, benzalkonium chloride, sodium chloride, sodium dihydrogen phosphate, and sodium hydrogen phosphate, heat and stir in a 60° C. water bath until clear and translucent, and cool to room temperature;
[0045] The third step is to add the mixed solution of the first step to the solution of the second step and make up to volume with water for injection;
[0046] The fourth step is to filter and sterilize the prepared eye drops through a 0.22 μm microporous filter membrane and aseptically package them.
[0047] The eye drops for inhibiting ocular pathological angiogenesis are used in the preparation of the treatment of ocular pathological angiogenesis.
[0048] Example 3
[0049] The present embodiment provides an eye drop for inhibiting pathological angiogenesis in the eye. The withaferin A eye drop contains the following ingredients by weight to volume ratio: 0.8 mg / L withaferin A, 8 g / L Tween 80, 5.6 g / L povidone K30, 0.1 g / L benzalkonium chloride, 6.2 g / L sodium chloride, 4 g / L sodium dihydrogen phosphate, 7.1 g / L disodium hydrogen phosphate, and the remainder is water for injection.
[0050] The dosage of the sodium dihydrogen phosphate and disodium hydrogen phosphate is based on adjusting the pH value of the eye drops to 6.8.
[0051] The amount of sodium chloride used is to adjust the osmotic pressure molar concentration ratio to 0.9.
[0052] The method of eye drops for inhibiting ocular pathological angiogenesis comprises the following steps:
[0053] The first step is to weigh withaferin A and Tween 80 in a corresponding weight-to-volume ratio, mix them and stir them evenly for later use;
[0054] Step 2: weigh corresponding weight-volume ratios of povidone K30, benzalkonium chloride, sodium chloride, sodium dihydrogen phosphate, and sodium hydrogen phosphate, heat and stir in a 60° C. water bath until clear and translucent, and cool to room temperature;
[0055] The third step is to add the mixed solution of the first step to the solution of the second step and make up to volume with water for injection;
[0056] The fourth step is to filter and sterilize the prepared eye drops through a 0.22 μm microporous filter membrane and aseptically package them.
[0057] The eye drops for inhibiting ocular pathological angiogenesis are used in the preparation of the treatment of ocular pathological angiogenesis.
[0058] The preparation method of the present invention includes but is not limited to various medically acceptable eye preparations such as eye drops, eye wash solutions, solid mixtures (dissolved before use), concentrated solutions (diluted before use), eye ointments, eye gels, etc.
[0059] The eye drops for inhibiting ocular pathological angiogenesis are used in the preparation of the treatment of ocular pathological angiogenesis.
[0060] The dissolution promoter may also be one of propylene glycol, poloxamer, polyethylene glycol, and β-cyclodextrin, or a mixture of any of Tween 80, propylene glycol, poloxamer, polyethylene glycol, and β-cyclodextrin.
[0061] The thickener can also be one of methylcellulose, polyvinyl alcohol, polyethylene glycol, sodium hyaluronate, hydroxypropyl methylcellulose, hydroxypropyl ethylcellulose, and carboxymethyl cellulose, or a mixture of any of methylcellulose, polyvinyl alcohol, polyethylene glycol, sodium hyaluronate, povidone, hydroxypropyl methylcellulose, hydroxypropyl ethylcellulose, and carboxymethyl cellulose.
[0062] The pH adjuster can also be one of boric acid, borate buffer, citrate buffer or a mixture of any of boric acid, borate buffer, phosphate buffer and citrate buffer. The amount of the pH adjuster is based on adjusting the pH value of the eye drops to 6.0-8.0.
[0063] The osmotic pressure regulator can also be one of potassium chloride, boric acid, glucose, and glycerol, or a mixture of any of sodium chloride, potassium chloride, boric acid, glucose, and glycerol; and the amount of the osmotic pressure regulator is used to adjust the osmotic pressure molar concentration ratio to 0.9 to 1.1.
[0064] The antibacterial agent can also be one of ethylhydroxybenzoate, benzalkonium bromide and polyquaternium-1, or a mixture of any of ethylhydroxybenzoate, benzalkonium chloride, benzalkonium bromide and polyquaternium-1.
[0065] In order to further demonstrate the effects and effects of the present invention, the in vivo experimental results of two animal models are provided as follows:
[0066] Withaferin A eye drops improve pathological angiogenesis in the cornea of mice induced by alkali burns, while withaferin A solution has no significant effect
[0067] This experiment selected the classic mouse corneal alkali burn model to induce corneal pathological angiogenesis. Healthy wild-type female C57 mice, 6-8 weeks old. All mice had shiny hair, no hair loss, no abnormalities in eye examination, clear refractive media, and normal fundus. They were randomly divided into: 1. Control group; 2. Alkali burn group; 3. Alkali burn + WFA (withaferin A) solution (DMSO dissolved) group; 4. Alkali burn + WFA eye drops group, 20 mice in each group. Among them, the concentration of withaferin A in groups 3 and 4 was the same, and both were given 4 times / day for eye drop intervention. After 14 days of intervention, the pathological angiogenesis of the cornea was scored under a microscope according to the following method: 0 = no neovascularization, no new blood vessels at the limbus; 1 = mild neovascularization, new blood vessels originating from the limbus; 2 = moderate neovascularization, blood vessels originating from the limbus and growing toward the center of the cornea; 3 = severe neovascularization, blood vessels starting from the limbus and reaching and / or passing through the center of the cornea. Figure 1 The results showed that withaferin A eye drops significantly improved the pathological angiogenesis of the mouse cornea, while withaferin A DMSO solution did not significantly improve the angiogenesis of the mouse ocular surface. Figure 1 NS = no difference, n = 5-6. **p < 0.01.
[0068] Immunofluorescence further confirmed that withaferin A eye drops significantly improved pathological angiogenesis in the cornea of mice induced by alkali burns
[0069] In order to further clarify the experimental results and reduce the errors caused by intuitive observation, we euthanized the mice on the 14th day of drug administration, removed the eyeballs by blunt dissection, used conventional immunofluorescence staining to mark new blood vessels with CD31 (red fluorescence) and cell nuclei with DAPI (blue fluorescence), and used confocal microscopy to image the flat cornea; Figure 2 The results showed that immunofluorescence further confirmed that withaferin A eye drops significantly improved pathological angiogenesis in the cornea of mice, and the results were statistically significant. Figure 2 n = 5-6. **p < 0.01.
[0070] Withaferin A eye drops improve corneal opacity induced by alkali burn in mice
[0071] This experiment still chose the classic mouse corneal alkali burn model to induce pathological corneal angiogenesis. Healthy wild-type male C57 mice, 6-8 weeks old. All mice had shiny hair without hair loss, no abnormalities were found in eye examination, clear refractive media, and normal fundus. They were randomly divided into: 1. control group; 2. alkali burn; 3. alkali burn + WFA eye drops group, 20 mice in each group. After 14 days of intervention, when the cornea was observed under a dissecting microscope, the opacity after the burn was scored: 0 = no opacity, the cornea is transparent; 1 = mild opacity, the iris and pupil areas are slightly blurred, and the iris and pupil are easily visible; 2 = moderate opacity, the iris and pupil are almost invisible; 3 = severe opacity, the iris or pupil is invisible; 4 = cornea is opaque, the iris and pupil are invisible. Figure 3 The results showed that withaferin A eye drops significantly improved corneal opacity caused by alkali burns in mice. Figure 3 n = 5-6. ***p < 0.001.
[0072] Withaferin A eye drops improve suture-induced pathological angiogenesis in the mouse cornea, while withaferin A solution has no significant effect
[0073] This experiment chose the classic suture method to induce pathological corneal angiogenesis. Healthy wild-type female ICR mice, aged 6-8 weeks. All mice had shiny hair without hair loss, no abnormalities were found in eye examination, clear refractive media, and normal fundus. They were randomly divided into: 1. Control group; 2. Suture group; 3. Suture + WFA (DMSO dissolved) solution group; 4. Suture + WFA eye drops group, 20 mice in each group. Among them, the concentration of withaferin A in groups 3 and 4 was the same, and both were given 4 times / day for eye drop intervention. After 14 days of intervention, the angiogenesis of each group was compared by counting the angiogenesis area under a microscope. Figure 4 The results showed that withaferin A eye drops significantly improved suture-induced pathological angiogenesis in the cornea of mice, while withaferin A DMSO solution did not significantly improve the angiogenesis on the mouse ocular surface. Figure 4 NS = no difference, ***p<0.001.
[0074] Example 6 Withaferin A eye drops improve pathological angiogenesis in the cornea of mice caused by suture method
[0075] In order to further clarify the experimental results and reduce the error caused by intuitive observation, we used conventional immunofluorescence staining method as in Example 3 and used confocal microscopy to image the flat cornea; Figure 5 The results showed that immunofluorescence further confirmed that withaferin A eye drops significantly improved the pathological angiogenesis of the cornea of mice caused by suture method, and the results were statistically significant. Figure 5 n = 5-6. **p < 0.01.
[0076] The in vivo experimental results of the above two animal models show that the use of only the solution of withaferin A has no effective therapeutic effect on pathological angiogenesis of the eye. The eye drops described in this patent, whose active ingredient is withaferin A, make withaferin A have better solubility and prolong its retention time on the ocular surface, and are used to treat pathological angiogenesis of the eye, especially pathological angiogenesis of the ocular surface, and are effective.
Claims
1. An eye drop for inhibiting pathological angiogenesis in the eye, characterized in that: The eye drops contain the following ingredients by weight-volume ratio: 0.01-0.8 mg / L withaferin A, 1-25 g / L dissolution promoter, 2-40 g / L thickener, 0.04-0.2 g / L antibacterial agent, appropriate amounts of isotonicity regulator and pH regulator, and the balance is water for injection.
2. The eye drops for inhibiting ocular pathological angiogenesis according to claim 1, characterized in that: The dissolution promoter is one of Tween 80, propylene glycol, poloxamer, polyethylene glycol, and beta-cyclodextrin, or a mixture of any of them.
3. The eye drops for inhibiting ocular pathological angiogenesis according to claim 1, characterized in that: The thickener is one or a mixture of any of methyl cellulose, polyvinyl alcohol, polyethylene glycol, sodium hyaluronate, povidone, hydroxypropyl methyl cellulose, hydroxypropyl ethyl cellulose, and carboxymethyl cellulose.
4. The eye drops for inhibiting ocular pathological angiogenesis according to claim 1, characterized in that: The pH regulator is one of boric acid, borate buffer, phosphate buffer, citrate buffer or a mixture of any of the above. The amount of the pH regulator is based on adjusting the pH value of the eye drops to 6.0-8.
0.
5. The eye drops for inhibiting ocular pathological angiogenesis according to claim 1, characterized in that: The osmotic pressure regulator is one of sodium chloride, potassium chloride, boric acid, glucose, and glycerol, or a mixture of any of them; and the dosage of the osmotic pressure regulator is to adjust the osmotic pressure molar concentration ratio to 0.9-1.
1.
6. The eye drops for inhibiting ocular pathological angiogenesis according to claim 1, characterized in that: The antibacterial agent is one of ethyl hydroxybenzoate, benzalkonium chloride, benzalkonium bromide and polyquaternium salt-1 or a mixture of any of them.
7. A method for preparing the eye drops for inhibiting ocular pathological angiogenesis according to any one of claims 1 to 6, characterized in that: The preparation method comprises the following steps: The first step is to weigh the withaferin A and the solubilizing agent in the corresponding weight-to-volume ratio, mix them and stir them evenly for later use; Step 2: Weigh the above thickener, pH adjuster, isotonic adjuster, and antibacterial agent in corresponding weight-volume ratios, heat and stir in a 60° C. water bath until clear and translucent, and cool to room temperature; The third step is to add the mixed solution of the first step to the solution of the second step and make up to volume with water for injection; The fourth step is to filter and sterilize the prepared eye drops through a 0.22 μm microporous filter membrane and aseptically package them.
8. Use of the eye drops for inhibiting ocular pathological angiogenesis according to any one of claims 1 to 6 in the preparation of an eye drop for treating ocular pathological angiogenesis.
Citation Information
Patent Citations
Eye drop with anti-cornea rebirth blood vessel function and preparation method thereof
CN101427997A
Application of Withaferin A in preparing drug for treating fundus ischemic disease
CN110151769A
Tyrosine kinase inhibitor ophthalmic preparation as well as preparation method and application thereof
CN116251186A
Withania somnifera composition, method of preparation and use thereof
US20210369804A1
Treatment of age-related degeneration and other eye diseases with apolipoprotein mimetics
WO2018139991A1
